Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) Enterprise Value (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Enterprise Value over the past 16 years, most recently at -$8.3 million for Q2 2025.

  • Quarterly results put Enterprise Value at -$8.3 million for Q2 2025, up 2.33% from a year ago — trailing twelve months through May 2025 was -$8.3 million (up 2.33% YoY), and the annual figure for FY2025 was -$8.3 million, up 2.33%.
  • Enterprise Value for Q2 2025 was -$8.3 million at Lifecore Biomedical, Inc. \De\, down from -$5.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for LFCR hit a ceiling of -$609000.0 in Q4 2021 and a floor of -$19.1 million in Q2 2023.
  • Median Enterprise Value over the past 5 years was -$2.7 million (2022), compared with a mean of -$4.9 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 75.4% in 2021 and later plummeted 1826.44% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Enterprise Value stood at -$609000.0 in 2021, then plummeted by 875.04% to -$5.9 million in 2022, then crashed by 221.51% to -$19.1 million in 2023, then surged by 50.47% to -$9.5 million in 2024, then rose by 12.59% to -$8.3 million in 2025.
  • The last three reported values for Enterprise Value were -$8.3 million (Q2 2025), -$5.4 million (Q1 2025), and -$9.5 million (Q4 2024) per Business Quant data.